OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+14.09%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$328M
AUM Growth
+$328M
(-9.1%)
Cap. Flow
-$47.8M
Cap. Flow
% of AUM
-14.57%
Top 10 Holdings %
Top 10 Hldgs %
48.5%
Holding
63
New
10
Increased
14
Reduced
12
Closed
20
Top Buys
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$9.31M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$6.57M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$5.75M |
| 4 |
Arvinas
ARVN
|
$4.84M |
| 5 |
Ocular Therapeutix
OCUL
|
$4.62M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$11.2M |
| 2 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$10.4M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$10.3M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
$9.31M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$7.7M |
Sector Composition
| 1 | Healthcare | 98.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Codexis
CDXS
$246M
| $24.9M | 7.58% | 1,350,000 -125,000 | -8% | -$2.3M |
|
2
Harrow
HROW
$1.44B
| $19.2M | 5.86% | 2,210,000 +410,000 | +23% | +$3.57M |
|
3
Axogen
AXGN
$743M
| $17.8M | 5.43% | 900,000 -200,000 | -18% | -$3.96M |
|
|
EPZM
4
DELISTED
Epizyme, Inc
EPZM
| $17.1M | 5.22% | 1,365,000 | – | – |
|
5
uniQure
QURE
$896M
| $16M | 4.88% | 205,000 | – | – |
|
|
ODT
6
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $15.6M | 4.75% | 425,000 +100,000 | +31% | +$3.67M |
|
|
7
Ocular Therapeutix
OCUL
$2.12B
| $13M | 3.96% | 2,950,000 +1,050,000 | +55% | +$4.62M |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $12.5M | 3.81% | 645,000 | – | – |
|
|
BPMC
9
DELISTED
Blueprint Medicines
BPMC
| $11.8M | 3.59% | 125,000 -5,000 | -4% | -$472K |
|
10
Avalo Therapeutics
AVTX
$122M
| $11.2M | 3.41% | 2,185,536 -114,464 | -5% | -$585K |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $10.6M | 3.23% | 280,000 | – | – |
|
12
PTC Therapeutics
PTCT
$3.92B
| $10.2M | 3.1% | 226,388 +12,588 | +6% | +$566K |
|
13
Cytokinetics
CYTK
$4.23B
| $10.1M | 3.09% | 900,000 +50,000 | +6% | +$563K |
|
14
TG Therapeutics
TGTX
$4.65B
| $9.95M | 3.03% | 1,150,000 -216,062 | -16% | -$1.87M |
|
|
EIDX
15
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $9.5M | 2.89% | 305,550 +105,550 | +53% | +$3.28M |
|
|
16
Lexicon Pharmaceuticals
LXRX
$400M
| $9.31M | 2.84% | +1,480,000 | New | +$9.31M |
|
17
Eton Pharmaceutcials
ETON
$464M
| $8.49M | 2.59% | 1,075,000 +310,227 | +41% | +$2.45M |
|
18
Dianthus Therapeutics
DNTH
$759M
| $7.89M | 2.41% | 535,000 +25,000 | +5% | +$369K |
|
|
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.7M | 2.35% | 195,000 +30,000 | +18% | +$1.18M |
|
|
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $6.99M | 2.13% | 310,000 -30,000 | -9% | -$677K |
|
21
FibroGen
FGEN
$47.8M
| $6.78M | 2.07% | 150,000 -50,000 | -25% | -$2.26M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.57M | 2% | +150,000 | New | +$6.57M |
|
|
CMRX
23
DELISTED
Chimerix, Inc.
CMRX
| $6.35M | 1.94% | 1,470,000 +510,000 | +53% | +$2.2M |
|
24
Xoma
XOMA
$392M
| $5.94M | 1.81% | 400,000 | – | – |
|
|
ATXI
25
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $5.86M | 1.79% | 930,000 +130,000 | +16% | +$819K |
|